Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to
Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment
period.
Stage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of
treatment with NVK-002 or Vehicle following 3 years of treatment in children with progressive
myopia.